Related Experiment Video
Updated: Mar 8, 2026
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Sunitinib side effects as surrogate biomarkers of efficacy
1Department of Medicine, University of British Columbia, BC Cancer Agency, Vancouver, BC, Canada.
Abstract:
With the proliferation of treatment options for the management of metastatic renal cell carcinoma (mRCC) over the past decade, predictive markers of response to therapy are becoming increasingly important. Sunitinib is commonly used in the first-line treatment of mRCC. Common mechanism-based adverse events, including hypertension, hypothyroidism, hand-foot syndrome, and neutropenia, have been explored as potential biomarkers of the clinical efficacy of sunitinib in mRCC and are reviewed in this article.
Insights
Predictive biomarkers for metastatic renal cell carcinoma (mRCC) are crucial with new treatments. This review explores common side effects of sunitinib, like hypertension and hypothyroidism, as potential indicators of treatment effectiveness in mRCC.
Area of Science:
- Oncology
- Pharmacology
Background:
- The management of metastatic renal cell carcinoma (mRCC) has evolved with numerous therapeutic options.
- Identifying predictive markers for treatment response is essential for optimizing patient outcomes.
Approach:
- This article reviews common mechanism-based adverse events associated with sunitinib, a first-line treatment for mRCC.
- The review examines hypertension, hypothyroidism, hand-foot syndrome, and neutropenia as potential biomarkers of sunitinib efficacy.
Key Points:
- Adverse events from targeted therapies can sometimes correlate with clinical benefit.
- Hypertension, hypothyroidism, hand-foot syndrome, and neutropenia are frequently observed with sunitinib treatment.
- These common toxicities may serve as early indicators of sunitinib's effectiveness in mRCC patients.
Conclusions:
- Exploring the relationship between adverse events and efficacy can guide treatment decisions in mRCC.
- Further research into these potential biomarkers may refine the use of sunitinib and improve patient care for metastatic renal cell carcinoma.
